• br Treatment KD is currently the treatment of choice for

  2022-01-13

  

  Treatment KD is currently the treatment of choice for GLUT1-DS. It is a high-fat, carbohydrate-restricted diet that mimics the metabolic state of fasting; so, the KD relies an exogenous rather than body fat for ketone production, thus maintaining ketosis without weight loss. As the developing br

• br Funding sources This work was supported in part by

  2022-01-12

  

  Funding sources This work was supported, in part, by NIH GM115388 to BGM. Acknowledgements Introduction Glucokinase (GCK) plays a central role in the regulation of glucose metabolism. Its activity is restricted to Doxofylline sale with important roles in whole-body glucose homeostasis [1].

• Overnight mg dexamethasone suppression testing DST of the

  2022-01-12

  

  Overnight 1-mg dexamethasone suppression testing (DST) of the BclI polymorphism carriers found them to have lower cortisol levels, suggesting an increased sensitivity to GCs with respect to the transrepression effect of cortisol on the POMC gene of the corticotroph pituitary cells [28]. The exact me

• cAMP is a key secondary

  2022-01-12

  

  cAMP is a key secondary messenger which transduces extracellular signals at glucagon receptors to intracellular effector molecules. cAMP-protein kinase A (PKA) pathway increases the gene expression of enzymes including phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase) whic

• br The bile acid farnesoid

  2022-01-12

  

  The “bile acid” farnesoid X receptor (FXR) The Farnesoid X Receptor (FXR) is a ligand-activated nuclear receptor belonging to the Nuclear Receptor superfamily of transcription factors exploiting various crucial functions in mammalian physiology, including reproduction, development and metabolism

• Species specificity of small molecular GPR agonists have bee

  2022-01-12

  

  Species specificity of small molecular GPR40 agonists have been reported by Takeda scientist. In the binding pocket of TM5, a Leu186 in human GPR40/FFA1 is replaced with Phe in rat, resulting in dramatic inter-species GPR40 activity discrepancy in certain scaffolds of small molecular GPR40 agonists.

• mimosine To date increasing evidence has demonstrated

  2022-01-12

  

  To date, increasing evidence has demonstrated that dysregulated lncRNAs are closely associated with the tumorigenesis and development of HCC via ceRNA modes [29,30]. LncRNAs could bind with special miRNAs and abrogate the inhibitory effect of these miRNAs on their targeted transcripts. For example,

• The present study also demonstrated that edoxaban inhibited

  2022-01-12

  

  The present study also demonstrated that edoxaban inhibited both free and clot-bound FXa activity. The IC50 values for free and clot-bound FXa in this study are well consistent with Ki values for free FXa and FXa incorporated in prothrombinase complex (0.561 and 2.98nM, respectively) in our previous

• In non Hodgkin lymphoma the catalytic

  2022-01-12

  

  In non-Hodgkin lymphoma the catalytic SET domain of the histone methyltransferase EZH2 is subject to recurrent heterozygous missense mutations . These alterations have been observed in ∼20% of patients with diffuse large B cell lymphoma (DLBCL) and ∼10% of patients with follicular lymphoma (FL). The

• The combination of HIV antigen and antibody

  2022-01-12

  

  The combination of HIV antigen and antibody testing with the fourth generation immunoassays shortens the window PS-1145 for HIV by detecting HIV antigen, which appears in the blood before seroconversion [3,5,11,12]. Analysis of the seroconversion panels indicated the Elecsys® HIV Duo assay has a go

• HIV incidence is often determined by

  2022-01-12

  

  HIV incidence is often determined by following cohorts of HIV-uninfected individuals and quantifying the rate of new HIV infections. HIV incidence can also be estimated using a cross-sectional study design, using laboratory assays to identify individuals who are likely to have recent HIV infection.

• Multi targeting agents are of major

  2022-01-12

  

  Multi-targeting agents are of major interest in modern drug design and discovery. Design of such compounds can be applied to H3R antagonists for the purpose of achieving optimum efficiency as performed for some preclinical candidates such as recently for contilisant (Bautista-Aguilera et al., 2017;

• Metal organic frameworks MOFs have

  2022-01-12

  

  Metal–organic frameworks (MOFs) have emerged over the past two decades with the potentials to act as promising materials in gas storage, chemical separation, catalyst, magnetism, sensing, and drug delivery etc (Du et al., 2013, Zhou and Kitagawa, 2014). Additionally, the secondary interactions, suc

• Type IIIa b the ligand dependent oncogenic Hh

  2022-01-12

  

  Type IIIa/b – the ligand dependent oncogenic Hh pathway (paracrine or reverse paracrine mode) is mediated by paracrine activation and is usually encountered in embryonic development, but also in installation and progression of cancer [58]. Specifically, Hh ligands secreted by malignant 4-iodo-SAHA

• N-3-oxo-dodecanoyl-L-Homoserine lactone Compound containing

  2022-01-12

  

  Compound containing, dimethylglutarimide P-cap, P propyl group, α-methylbenzyl urea resulted in inhibitor with much improved binding (=0.064μM) and EC=0.3μM. This was an aza-peptide analog with an EC comparable to our first generation clinical candidate . Analog was evaluated for its selectivity aga

16357 records 520/1091 page Previous Next First page 上5页 516517518519520 下5页 Last page